Just before the end of 2025, an oral version of a GLP-1 drug specifically used for weight management moved much closer to reality. On December 22, the U.S. Food and Drug Administration (FDA) approved ...

The FDA on Monday approved a daily pill version of Novo Nordisk’s Wegovy, making it the first oral GLP-1 obesity treatment ...

Beginning in January 2026, this pill - developed by Danish pharmaceutical company Novo Nordisk - will become a daily option ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Wegovy (semaglutide) is approved by the U.S. Food and Drug Administration (FDA) for weight loss and weight management in people with ...

Wegovy's new pill has been approved in the US, offering a needle-free option with a lower starting price than injections.

Pharmacists urge patients to avoid buying the injections from beauty salons, unregulated sellers, an users with leftover pens ...

As of February 2025, the semaglutide injection (Ozempic, Wegovy) shortage was resolved. As a result, compounded semaglutide ...

In the studies the company submitted to the FDA, people who took the daily Wegovy pill lost about the same amount of ...

The FDA has approved the first-ever Wegovy pill for weight loss, with the oral GLP-1 offering a 16.6% average weight ...

A pill version of the popular GLP-1 weight-loss drug Wegovy has been green-lit for use in the U.S. Here’s what that means for ...

FDA has approved Wegovy pill, offering oral alternative to injections for obesity, delivering 14% average weight loss over 64 ...

On Monday evening, the Food and Drug Administration approved Novo Nordisk’s high-dose oral formulation of semaglutide for ...